Literature DB >> 25997944

Neurogenic mechanisms underlying the rapid onset of sympathetic responses to intermittent hypoxia.

Steve Mifflin1, J Thomas Cunningham2, Glenn M Toney3.   

Abstract

Sleep apnea (SA) leads to metabolic abnormalities and cardiovascular dysfunction. Rodent models of nocturnal intermittent hypoxia (IH) are used to mimic arterial hypoxemias that occur during SA. This mini-review focuses on our work examining central nervous system (CNS) mechanisms whereby nocturnal IH results in increased sympathetic nerve discharge (SND) and hypertension (HTN) that persist throughout the 24-h diurnal period. Within the first 1-2 days of IH, arterial pressure (AP) increases even during non-IH periods of the day. Exposure to IH for 7 days biases nucleus tractus solitarius (NTS) neurons receiving arterial chemoreceptor inputs toward increased discharge, providing a substrate for persistent activation of sympathetic outflow. IH HTN is blunted by manipulations that reduce angiotensin II (ANG II) signaling within the forebrain lamina terminalis suggesting that central ANG II supports persistent IH HTN. Inhibition of the hypothalamic paraventricular nucleus (PVN) reduces ongoing SND and acutely lowers AP in IH-conditioned animals. These findings support a role for the PVN, which integrates information ascending from NTS and descending from the lamina terminalis, in sustaining IH HTN. In summary, our findings indicate that IH rapidly and persistently activates a central circuit that includes the NTS, forebrain lamina terminalis, and the PVN. Our working model holds that NTS neuromodulation increases transmission of arterial chemoreceptor inputs, increasing SND via connections with PVN and rostral ventrolateral medulla. Increased circulating ANG II sensed by the lamina terminalis generates yet another excitatory drive to PVN. Together with adaptations intrinsic to the PVN, these responses to IH support rapid onset neurogenic HTN.
Copyright © 2015 the American Physiological Society.

Entities:  

Keywords:  central nervous system; intermittent hypoxia; sympathetic nervous system

Mesh:

Year:  2015        PMID: 25997944      PMCID: PMC4683347          DOI: 10.1152/japplphysiol.00198.2015

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  66 in total

1.  Contribution of tonic chemoreflex activation to sympathetic activity and blood pressure in patients with obstructive sleep apnea.

Authors:  K Narkiewicz; P J van de Borne; N Montano; M E Dyken; B G Phillips; V K Somers
Journal:  Circulation       Date:  1998-03-17       Impact factor: 29.690

2.  Intermittent hypoxia-induced glucose intolerance is abolished by α-adrenergic blockade or adrenal medullectomy.

Authors:  Jonathan C Jun; Mi-Kyung Shin; Ronald Devera; Qiaoling Yao; Omar Mesarwi; Shannon Bevans-Fonti; Vsevolod Y Polotsky
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-10-14       Impact factor: 4.310

Review 3.  The sympathetic nervous system and obstructive sleep apnea: implications for hypertension.

Authors:  K Narkiewicz; V K Somers
Journal:  J Hypertens       Date:  1997-12       Impact factor: 4.844

4.  Angiotensin II type 1a receptors in subfornical organ contribute towards chronic intermittent hypoxia-associated sustained increase in mean arterial pressure.

Authors:  Ashwini Saxena; Joel T Little; T Prashant Nedungadi; J Thomas Cunningham
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-12-24       Impact factor: 4.733

5.  Glucocorticoids act in the dorsal hindbrain to increase arterial pressure.

Authors:  Deborah A Scheuer; Andrea G Bechtold; Sylvan S Shank; Susan F Akana
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-09-25       Impact factor: 4.733

6.  Chronic intermittent hypoxia impairs endothelium-dependent dilation in rat cerebral and skeletal muscle resistance arteries.

Authors:  Shane A Phillips; E B Olson; Barbara J Morgan; Julian H Lombard
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-09-25       Impact factor: 4.733

7.  Chronic intermittent hypoxia increases sympathetic control of blood pressure: role of neuronal activity in the hypothalamic paraventricular nucleus.

Authors:  Amanda L Sharpe; Alfredo S Calderon; Mary Ann Andrade; J Thomas Cunningham; Steven W Mifflin; Glenn M Toney
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-10-04       Impact factor: 4.733

8.  Obese patients with obstructive sleep apnoea syndrome show a peculiar alteration of the corticotroph but not of the thyrotroph and lactotroph function.

Authors:  F Lanfranco; L Gianotti; S Pivetti; F Navone; R Rossetto; F Tassone; V Gai; E Ghigo; M Maccario
Journal:  Clin Endocrinol (Oxf)       Date:  2004-01       Impact factor: 3.478

Review 9.  Hypertension and obstructive sleep apnea.

Authors:  Bradley G Phillips; Virend K Somers
Journal:  Curr Hypertens Rep       Date:  2003-10       Impact factor: 5.369

10.  Regulation of hypoxia-inducible factor-α isoforms and redox state by carotid body neural activity in rats.

Authors:  Ying-Jie Peng; Guoxiang Yuan; Shakil Khan; Jayasri Nanduri; Vladislav V Makarenko; Vaddi Damodara Reddy; Chirag Vasavda; Ganesh K Kumar; Gregg L Semenza; Nanduri R Prabhakar
Journal:  J Physiol       Date:  2014-06-27       Impact factor: 5.182

View more
  15 in total

Review 1.  Regulation of sympathetic vasomotor activity by the hypothalamic paraventricular nucleus in normotensive and hypertensive states.

Authors:  Roger A Dampney; Lisete C Michelini; De-Pei Li; Hui-Lin Pan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-08-10       Impact factor: 4.733

2.  Glucose-Lowering by Leptin in the Absence of Insulin Does Not Fully Rely on the Central Melanocortin System in Male Mice.

Authors:  Ashish K Singha; Junya Yamaguchi; Nancy S Gonzalez; Newaz Ahmed; Glenn M Toney; Teppei Fujikawa
Journal:  Endocrinology       Date:  2019-03-01       Impact factor: 4.736

3.  Oxidative stress augments chemoreflex sensitivity in rats exposed to chronic intermittent hypoxia.

Authors:  Barbara J Morgan; Melissa L Bates; Rodrigo Del Rio; Zunyi Wang; John M Dopp
Journal:  Respir Physiol Neurobiol       Date:  2016-09-03       Impact factor: 1.931

4.  Hypothalamic PVN contributes to acute intermittent hypoxia-induced sympathetic but not phrenic long-term facilitation.

Authors:  Megan B Blackburn; Mary Ann Andrade; Glenn M Toney
Journal:  J Appl Physiol (1985)       Date:  2017-12-21

Review 5.  Role of Carotid Body in Intermittent Hypoxia-Related Hypertension.

Authors:  Rodrigo Iturriaga; María Paz Oyarce; Ana Carolina Rodrigues Dias
Journal:  Curr Hypertens Rep       Date:  2017-05       Impact factor: 5.369

6.  CRHR2 (Corticotropin-Releasing Hormone Receptor 2) in the Nucleus of the Solitary Tract Contributes to Intermittent Hypoxia-Induced Hypertension.

Authors:  Lei A Wang; Dianna H Nguyen; Steve W Mifflin
Journal:  Hypertension       Date:  2018-10       Impact factor: 10.190

7.  Sympathetic neural recruitment strategies following acute intermittent hypoxia in humans.

Authors:  Elizabeth P Ott; Dain W Jacob; Sarah E Baker; Walter W Holbein; Zachariah M Scruggs; J Kevin Shoemaker; Jacqueline K Limberg
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2020-04-08       Impact factor: 3.619

8.  Caspase lesions of PVN-projecting MnPO neurons block the sustained component of CIH-induced hypertension in adult male rats.

Authors:  Alexandria B Marciante; Lei A Wang; Joel T Little; J Thomas Cunningham
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-11-01       Impact factor: 4.733

9.  Central AT1 receptor signaling by circulating angiotensin II is permissive to acute intermittent hypoxia-induced sympathetic neuroplasticity.

Authors:  Caroline G Shimoura; Mary Ann Andrade; Glenn M Toney
Journal:  J Appl Physiol (1985)       Date:  2020-04-02

10.  N-Acetylcysteine reduces hyperacute intermittent hypoxia-induced sympathoexcitation in human subjects.

Authors:  Noah P Jouett; Gilbert Moralez; Daniel W White; Wendy L Eubank; Shande Chen; Jun Tian; Michael L Smith; Matthew C Zimmerman; Peter B Raven
Journal:  Exp Physiol       Date:  2016-02-04       Impact factor: 2.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.